Focused On-demand Library for Solute carrier family 4 member 11

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We employ our advanced, specialised process to create targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q8NBS3

UPID:

S4A11_HUMAN

Alternative names:

Sodium borate cotransporter 1

Alternative UPACC:

Q8NBS3; B4DKC8; B4DKX9; G3V1M3; Q2TB62; Q2TB63; Q9BXF4; Q9NTW9

Background:

Solute carrier family 4 member 11 (SLC4A11), also known as Sodium borate cotransporter 1, plays a crucial role in maintaining corneal transparency and cellular homeostasis. It functions as a multifunctional transporter, influencing cell morphology and differentiation. Its activities range from acting as a voltage-dependent Na(+)-coupled B(OH)4(-) cotransporter to participating in cellular redox balance and oxidative stress response in the corneal endothelium.

Therapeutic significance:

SLC4A11's dysfunction is linked to several corneal diseases, including Corneal dystrophy and perceptive deafness, Corneal endothelial dystrophy, and Fuchs endothelial corneal dystrophy 4. These associations highlight its potential as a target for therapeutic intervention in ocular diseases. Understanding the role of SLC4A11 could open doors to potential therapeutic strategies.